TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21194608

Group type: EXPERIMENTAL
Intervention: Test formulation (generic risperidone tablet)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference formulation (branded risperidone tablet)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 22
Study: 17662757

Group type: EXPERIMENTAL
Intervention: Self-help book with seven weekly phone calls
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 72
Study: 15970632

Group type: EXPERIMENTAL
Intervention: Stalevo (levodopa, carbidopa, entacapone)
Number of subjects: 176

Group type: COMPARATOR
Intervention: levodopa/DDCI plus entacapone (Comtess/Comtan)
Number of subjects: 176
Study: 12584871

Group type: EXPERIMENTAL
Intervention: High-structure, behaviorally-oriented (HSB) individual counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-structure, facilitative (LSF) individual counseling
Number of subjects: 0
Study: 10354805

Group type: EXPERIMENTAL
Intervention: Secondary tasks with different cognitive processing combinations (orthographic, phonemic, and semantic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized secondary task techniques
Number of subjects: 0
Study: 7864421

Group type: EXPERIMENTAL
Intervention: Vecuronium 20 micrograms/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vecuronium 10 micrograms/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vecuronium 15 micrograms/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vecuronium 10 micrograms/kg, 15 micrograms/kg, and 20 micrograms/kg
Number of subjects: 42
Study: 2040254

Group type: EXPERIMENTAL
Intervention: 2.0% COHb exposure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 3.9% COHb exposure
Number of subjects: 63
Study: 7126399

Group type: EXPERIMENTAL
Intervention: i.m. Glycopyrrolate 7.5 micrograms kg‐1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: i.v. Atropine 15 micrograms kg‐1
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no anticholinergic premedication)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 160
Study: 30526280

Group type: EXPERIMENTAL
Intervention: 6-week EF instruction exercises
Number of subjects: 32
Study: 29563636

Group type: EXPERIMENTAL
Intervention: nintedanib (200 mg bid)
Number of subjects: 93

Group type: COMPARATOR
Intervention: sorafenib (400 mg bid)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: nintedanib
Number of subjects: 93

Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 93
Study: 27976604

Group type: EXPERIMENTAL
Intervention: Guided crockery set (CS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Calibrated serving spoon set (SS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both tools (CS and SS)
Number of subjects: 29
Study: 24287077

Group type: EXPERIMENTAL
Intervention: Extensive intraoperative peritoneal lavage + arm
Number of subjects: 300

Group type: COMPARATOR
Intervention: Extensive intraoperative peritoneal lavage - arm
Number of subjects: 300
Study: 23622850

Group type: EXPERIMENTAL
Intervention: ARC intervention
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control
Number of subjects: 393
Study: 21158329

Group type: EXPERIMENTAL
Intervention: 2 g intravenous paracetamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 g intravenous paracetamol
Number of subjects: 60
Study: 18528411

Group type: EXPERIMENTAL
Intervention: PulsePen
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Complior
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PulseTrace
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reference method (simultaneous acquisition of pressure waves using two tonometers)
Number of subjects: 50
Study: 16671428

Group type: EXPERIMENTAL
Intervention: SAH patients
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: SAH and ROSC‐SAH
Number of subjects: 143
Study: 14581254

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg with moderate intensity counseling
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg with moderate intensity counseling
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg
Number of subjects: 1524
Study: 11002229

Group type: EXPERIMENTAL
Intervention: Conformal external beam radiation therapy
Number of subjects: 43
Study: 8971287

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1593689

Group type: EXPERIMENTAL
Intervention: site release vaginal pH buffer cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 6520800

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 42
Study: 30951602

Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 28791531

Group type: EXPERIMENTAL
Intervention: Psychosocial-behavioral intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 199
Study: 27267710

Group type: COMPARATOR
Intervention: Probiotic Visbiome at 900 billion bacteria daily
Number of subjects: 76
Study: 25059544

Group type: EXPERIMENTAL
Intervention: Grip on Challenging Behavior care program
Number of subjects: 17
Study: 22678090

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure-lowering treatment
Number of subjects: 404
Study: 20175871

Group type: EXPERIMENTAL
Intervention: Pocket cards (PC)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Pocket digital assistant (PDA)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: eAlerts
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Control group (no CDSS)
Number of subjects: 1085
Study: 17535839

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1740

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1740

Group type: COMPARATOR
Intervention: Smaller practice size (greater than eight GPs)
Number of subjects: 1740

Group type: COMPARATOR
Intervention: Older GPs
Number of subjects: 1740
Study: 16036009

Group type: EXPERIMENTAL
Intervention: Home videoconferencing (n = 14)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ad hoc telephone support (n = 9)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Regular telephone calls (n = 13)
Number of subjects: 36
Study: 12107216

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 10443602

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isoflurane and Sevoflurane
Number of subjects: 39

Group type: COMPARATOR
Intervention: All three anesthetic agents
Number of subjects: 39
Study: 7484061

Group type: EXPERIMENTAL
Intervention: Posatirelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citicoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 0
Study: 1978862

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: H1-receptor antagonist, local decongestants, and antiseptic gargles
Number of subjects: 75

Group type: COMPARATOR
Intervention: Alum, salt or Dispirin gargles
Number of subjects: 75
Study: 895764

Group type: EXPERIMENTAL
Intervention: Immediate regional-lymph-node dissection
Number of subjects: 553

Group type: COMPARATOR
Intervention: Delayed regional-lymph-node dissection (at the time of appearance of metastases)
Number of subjects: 553
Study: 31848626

Group type: EXPERIMENTAL
Intervention: Balance group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Strength group
Number of subjects: 151

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 151
Study: 31768803

Group type: EXPERIMENTAL
Intervention: Valsartan plus activated vitamin D (calcitriol) 0.5 μg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan 160 mg/day
Number of subjects: 0
Study: 30700351

Group type: EXPERIMENTAL
Intervention: Amphotericin B combined with autologous serum injection
Number of subjects: 96

Group type: COMPARATOR
Intervention: Amphotericin B alone (Control group)
Number of subjects: 96
Study: 28866453

Group type: EXPERIMENTAL
Intervention: Ponseti method
Number of subjects: 15

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 15
Study: 26179651

Group type: EXPERIMENTAL
Intervention: Therapist delivered cognitive behavioural therapy (TCBT) plus treatment as usual (TAU)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioural therapy (WBCBT) plus treatment as usual (TAU)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 495
Study: 23864492

Group type: EXPERIMENTAL
Intervention: 3 months bicycle endurance training
Number of subjects: 13

Group type: COMPARATOR
Intervention: Reference group (males without diabetes)
Number of subjects: 13
Study: 16968502

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg q.a.m.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (Pantoprazole and Placebo)
Number of subjects: 39
Study: 15220766

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 320

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 320

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 320
Study: 10731533

Group type: EXPERIMENTAL
Intervention: Bilateral ovarian wedge resection (OWR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study: 9116222

Group type: EXPERIMENTAL
Intervention: Primed stems
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unprimed stems
Number of subjects: 40
Study: 1548525

Group type: EXPERIMENTAL
Intervention: Prednisone and doxorubicin (arm 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: VM-26 and Ara-C (arm 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Overall treatment
Number of subjects: 80
Study: 2860990

Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg twice a day, increased to a maximum of 400 mg twice a day)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 31515736

Group type: EXPERIMENTAL
Intervention: Full team training program (didactic training and virtual simulation)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Didactic part of the training program
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 207
Study: 27995340

Group type: EXPERIMENTAL
Intervention: Genetic polymorphism in TXBA2R (rs1131882)
Number of subjects: 303
Study: 26093794

Group type: EXPERIMENTAL
Intervention: Telemedical intervention for diabetic foot ulcers
Number of subjects: 0
Study: 24225010

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) with home exercise (HE)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise plus home exercise (HE)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Home exercise (HE) alone
Number of subjects: 241
Study: 21178182

Group type: EXPERIMENTAL
Intervention: Initial implanting (I-implant)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Terminal implanting (T-implant)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Ractopamine hydrochloride (RAC, 200 mg/(animal/d))
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: I-implant
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: T-implant
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: RAC
Number of subjects: 291

Group type: COMPARATOR
Intervention: TRT1 and TRT2 (1 implant)
Number of subjects: 291
Study: 19154822

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 198

Group type: COMPARATOR
Intervention: Wait-and-see approach with ergonomic advice
Number of subjects: 198
Study: 17705242

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced targeted biopsy (5 cores)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Systematic biopsy (10 cores)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced targeted biopsy cores
Number of subjects: 100

Group type: COMPARATOR
Intervention: Systematic biopsy cores
Number of subjects: 100
Study: 14756612

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 73
Study: 11123733

Group type: EXPERIMENTAL
Intervention: Ketoprofen (0.3-3 mg x kg(-1))
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 11214557

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) for 5 days
Number of subjects: 335

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (A-C) for 10 days
Number of subjects: 335

Group type: COMPARATOR
Intervention: Erythromycin estolate (EE) for 10 days
Number of subjects: 335
Study: 8206813

Group type: EXPERIMENTAL
Intervention: Local union formalization
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Local union centralization
Number of subjects: 539
Study: 2521549

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Volatile anesthetics
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: All anesthetics
Number of subjects: 1012
Study: 31764984

Group type: EXPERIMENTAL
Intervention: High dialysate Mg (2.0 mEq/L)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard dialysate Mg (1.0 mEq/L)
Number of subjects: 57
Study: 30580460

Group type: EXPERIMENTAL
Intervention: digoxin + furosemide (0·125%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: digoxin (0·125%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: furosemide (0·125%)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 28739832

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3220

Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3220
Study: 25306517

Group type: EXPERIMENTAL
Intervention: Immediate rotator cuff repair with capsular release (group I)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delayed rotator cuff repair after 6 months of rehabilitation (group II)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 63
Study: 23538449

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 1 (past‐year abstinence)
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 2 (low‐risk drinking)
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 3 (mild to moderate alcohol misuse)
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 4 (severe alcohol misuse)
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Comparison of zone 4 to zone 2
Number of subjects: 1037
Study: 21916619

Group type: EXPERIMENTAL
Intervention: Unmet Social Support Score (USSS)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Unmet emotional social support
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Unmet instrumental social support
Number of subjects: 190
Study: 19533481

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 16920680

Group type: EXPERIMENTAL
Intervention: MicroFET 4 hand-grip dynamometer
Number of subjects: 0
Study: 15111227

Group type: EXPERIMENTAL
Intervention: Feedback provided; St=1000 ms, ISI=2700 ms, order Co-St
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback; St=1000 ms, ISI=900 or 2700 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: St=50 ms, ISI=100, 300, 900, or 2700 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: St=1000 ms, ISI=100, 300, 900, or 2700 ms
Number of subjects: 0
Study: 11259239

Group type: EXPERIMENTAL
Intervention: Prednisolone oral solution
Number of subjects: 78

Group type: COMPARATOR
Intervention: Crushed prednisolone tablets
Number of subjects: 78
Study: 9348384

Group type: EXPERIMENTAL
Intervention: Encircled mesh technique (Group A)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Nonencircled mesh technique (Group B)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Mixed technique (Group C)
Number of subjects: 191
Study: 8294084

Group type: EXPERIMENTAL
Intervention: Yohimbine (2 mg tid)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2436343

Group type: EXPERIMENTAL
Intervention: Haemonetics Cell Saver
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Gambro Hollow Fibre Hemofilter
Number of subjects: 46

Group type: COMPARATOR
Intervention: Untreated oxygenator contents
Number of subjects: 46
Study: 31732448

Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet 30 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28974102

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 28028373

Group type: EXPERIMENTAL
Intervention: Nitrous oxide inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure oxygen inhalation (Control)
Number of subjects: 0
Study: 24328992

Group type: EXPERIMENTAL
Intervention: CoreControl® (CC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ThermoTube (TT)
Number of subjects: 9
Study: 22764846

Group type: EXPERIMENTAL
Intervention: Oral zinc (220 mg twice daily, equivalent to 50 mg elemental zinc twice daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 20338667

Group type: EXPERIMENTAL
Intervention: CDC-diagnosed SSI
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CDC criteria
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ASEPSIS score
Number of subjects: 54
Study: 18757665

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg per day
Number of subjects: 3519

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 3519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3519
Study: 15844683

Group type: EXPERIMENTAL
Intervention: Exposure group treatment (n = 33)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting period (n = 25)
Number of subjects: 58
Study: 12190100

Group type: EXPERIMENTAL
Intervention: INF‐alpha + GM‐CSF for 3 months followed by INF‐alpha alone for 9 months (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: INF‐alpha for 12 months (n = 22)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: INF‐alpha + GM‐CSF
Number of subjects: 45

Group type: COMPARATOR
Intervention: INF‐alpha
Number of subjects: 45
Study: 11012554

Group type: EXPERIMENTAL
Intervention: Doxorubicin (Dox)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Etoposide (Eto)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ifosfamide (Ifo)
Number of subjects: 24
Study: 8798375

Group type: EXPERIMENTAL
Intervention: ATLS course
Number of subjects: 32

Group type: COMPARATOR
Intervention: non-ATLS group
Number of subjects: 32
Study: 2050321

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (5 MU/m2 for 4 months and then 3 MU/m2 for another 8 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b
Number of subjects: 61
Study: 6860532

Group type: EXPERIMENTAL
Intervention: Metolazone 2.5 mg + Spironolactone 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metolazone 0.625 mg + Spironolactone 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metolazone 1.25 mg + Spironolactone 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Metolazone 2.5 mg alone
Number of subjects: 12
Study: 31571095

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Nonusers of statins
Number of subjects: 1509
Study: 29073902

Group type: EXPERIMENTAL
Intervention: Mixed primary root canal filling (MPRCF: zinc oxide‐eugenol [ZOE], iodoform, calcium hydroxide)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Zinc oxide‐eugenol (ZOE)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 155
Study: 25933490

Group type: EXPERIMENTAL
Intervention: Fish oil group (FO) - 3 g/d of fish oil ω‐3 fatty acids (10 capsules)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil group (OO) - 10 mL/d of extra virgin olive oil at lunch and dinner
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fish oil and extra virgin olive oil group (FOO) - 3 g/d of fish oil ω‐3 fatty acids and 10 mL/d of extra virgin olive oil
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (CG) - instructed to maintain their usual diet
Number of subjects: 102
Study: 23329628

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 40
Study: 22151987

Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (Arm I)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel (Arm II)
Number of subjects: 65
Study: 19321022

Group type: EXPERIMENTAL
Intervention: General Psychiatric Management (GPM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Psychotropic medications (mean number prescribed: 2.3)
Number of subjects: 50
Study: 16501729

Group type: EXPERIMENTAL
Intervention: Bednet protection from birth (group A)
Number of subjects: 3387

Group type: COMPARATOR
Intervention: Bednet protection from age 6 months (group B)
Number of subjects: 3387